Physician profile
Kerin B Hausknecht
NPI 1295750099
$1,682.52
in general payments reported to CMS, 2019-2025
16 companies · $852 in 2025
The $852 reported for 2025 was more than what 83% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $93.07 · 2023: $505 · 2024: $233 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,589.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $344.12 | 2022-2025 | Ultomiris, Soliris |
| Abbvie INC. | $280.20 | 2022-2025 | |
| Sk Life Science, INC. | $177.80 | 2025 | |
| Ucb, INC. | $160.60 | 2023-2025 | Briviact, Fintepla, Nayzilam |
| Eisai INC. | $147.97 | 2023-2025 | |
| Grifols USA, LLC | $119.97 | 2023-2025 | Gamunex-C |
| Pfizer INC. | $73.46 | 2023-2025 | |
| Neurelis, INC. | $67.80 | 2024-2025 | Valtoco |
| Lundbeck LLC | $67.42 | 2023 | Vyepti |
| Argenx US, INC. | $64.14 | 2025 | Vyvgart |
| Biohaven Pharmaceutical Holding Company Ltd. | $40.18 | 2022 | |
| Chiesi USA, INC. | $39.38 | 2023-2025 | Cleviprex |
| Medtronic, INC. | $31.62 | 2025 | Percept Pc Brainsense |
| Jazz Pharmaceuticals INC. | $23.60 | 2025 | |
| Octapharma USA, INC. | $22.95 | 2023 | Panzyga |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $21.31 | 2025 | Cervical-Stim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerin Hausknecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.